Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results

This study shows that EDTA decalcification minimally affects receptor expression results. The incidence of clinically relevant discordance between the primary tumor and bone metastases is low. These findings support that bone biopsies can reliably be used to assess receptor status.
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research

Related Links:

ConclusionsPredictive markers displayed a yearly similar distribution in breast cancer cases independently of grading or of intrinsic subtypes. These results point to a qualitative high performance of predictive marker assessment in breast cancer, corresponding to expected on average positivity rate per marker and per year. It is recommended to monitor positivity rate of ER, PR, Ki67 and Her2 yearly or periodically to comply with quality assurance requirements.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
We present a pathological perspective of our experience. PMID: 31598347 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Authors: Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J Abstract Purpose: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography (US) size was compared based on breast cancer subtypes. In addition, we investigated the positive margin rates. Methods: Patients with invasive breast cancer who underwent preoperative breast MRI and US between 2011 and 2016 were included in the study. Lin's concordance correlation coefficient was used to measure the corr...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
ConclusionFurther functional studies to decipher the role of IDH2 and its mechanism of action as a driver of BC progression and LVI are warranted.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   ERBB2 Overexpression;   HER2 Positive Breast Carcinoma;   Metastatic Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8;   Refractory Breast Carcinoma Interventions:   Drug: Alpha-tocopheryloxyacetic Acid;   Biological: Trastuzumab Sponsors:   University of Washington;   National Cancer Institute (NCI);   Veana Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: High p16 protein expression was associated with ER-positive, PR-negative, and HER2-negative tumors which is associated with poor prognosis. p16 protein expression may be used as a prognostic indicator to predict treatment response to hormonal therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Authors: Bielawski K, Rhone P, Bielawska S, Rosc D, Brkic A, Zarychta E, Ruszkowska-Ciastek B Abstract Heparanase concentration is low in normal epithelia cells but its overexpression is reported in many carcinomas, including sarcomas and haematological malignancies. The purpose of this study was to investigate the association with selected angiogenic parameters as well as in the number of circulating endothelial progenitors (EPCs) in respect to low, moderate and high concentrations of heparanase. Also, we estimated the diagnostic usefulness of the heparanase concentration for disease recurrence prediction in breas...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research
ConclusionsDevelopment of PD-1 B-cell vaccine was successful, showing no evidence of toxicity or autoimmunity in mice, rabbits and beagle dogs. The combination vaccines could provide improved outcomes in early stage disease sparing patients the toxicity of chemotherapy. A phase 1 clinical trial with the PD-1 vaccine is under planning.Legal entity responsible for the studyThe authors.FundingNIH; Imugene.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Acetic Acid | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Hormones | Pathology | Study